Make better investment decisions with Simply Wall St’s easy, visual tools that give you a competitive edge.
-
Agilent Technologies (NYSE:A) secured expanded European approval for its PD-L1 IHC 22C3 pharmDx test for ovarian cancer applications.
-
The CE-marked indication now covers patients with ovarian, fallopian tube, and primary peritoneal carcinoma in the EU.
-
The move strengthens Agilent’s oncology diagnostics portfolio and supports wider use of targeted cancer therapies in Europe.
For readers looking to explore more stocks tied to the rise of data driven tools in cancer care and diagnostics, a focused set of healthcare AI ideas is available at 42 healthcare AI stocks
NYSE:A 1-Year Stock Price Chart
Agilent Technologies sits at the intersection of life sciences tools and clinical diagnostics, supplying instruments and tests that support research labs, drug developers, and hospitals. The stock has returned 25.0% over the past year and trades at $141.34. This gives investors a sense of how the market has recently viewed its role in areas like oncology testing and broader lab workflows.
How does this PD-L1 approval actually change things for Agilent Technologies?
The new European indication for Agilent Technologies’ PD-L1 IHC 22C3 pharmDx test formally ties the assay to epithelial ovarian, fallopian tube, and primary peritoneal carcinoma. It is now the eighth CE marked use of this test in the EU, which broadens the pool of patients who can be assessed for potential treatment with Merck’s Keytruda. For Agilent, that means its reagent and instrument footprint can be used in more oncology workflows inside the same hospital labs. The approval also adds another use case to the company’s menu of companion diagnostics, which can support stickier relationships with oncology centers and drug developers that rely on consistent testing protocols across multiple tumor types.
What does this mean for the Agilent Technologies Narrative in diagnostics?
The approval fits neatly with the Narrative that Agilent is leaning into recurring, clinically oriented revenue. PD-L1 IHC 22C3 pharmDx is already used across several tumor types, and each label expansion can help drive incremental consumables usage on existing platforms rather than requiring a new hardware sale. When combined with acquisitions such as Biocare Medical, the ovarian cancer indication points to a broader push to scale oncology diagnostics even as competition from groups like Danaher remains intense. Investors who follow Agilent’s shift toward higher margin diagnostics, software, and services can treat this as one more data point that the company is adding new tests to its installed base instead of relying only on instrument replacement cycles.
What should investors watch next from this PD-L1 expansion?
The key figure to track from here is how many additional CE marked indications Agilent secures for PD-L1 IHC 22C3 pharmDx over the next 12 to 18 months, beyond the current total of eight in the EU. Each new tumor type can widen test volumes without major new capital spending. Investors can also monitor future quarterly disclosures for any commentary on companion diagnostic revenue trends tied to PD-L1 testing and the Biocare Medical acquisition, which would show how quickly these new labels are feeding into the broader oncology diagnostics business.
For the full picture including more risks and rewards, check out the complete Agilent Technologies analysis. Alternatively, you can check out the community page for Agilent Technologies to see how other investors believe this latest news will impact the company’s narrative.
Stay updated on the most important news stories for Agilent Technologies by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Agilent Technologies.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include A.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com